Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
See detailInfluencia de la modalidad de presentación del trigo
Piron, Fabien ULg; Philippart de Foy, Martin; Thewis, André ULg et al

Article for general public (2010)

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailInfluenţa fertilizării minerale asupra producţiei la amestecul de lucernă şi golomăţ în anul III de vegetaţie
Muntianu, Iulian Constantin; Stavarache, Mihai; Ciobanu, Ciprian et al

in Ţenu, Ioan; Vîntu, Vasile; Jităreanu, Gerard (Eds.) Durable Agriculture and Food Security – Priority objectives in research activity of the Ph.D. students from the UASVM Iasi (2012, December 07)

This study was conducted during three production cycles of the third year of vegetation. The main objective was to determine the production of dry matter (DM) and crude protein (CP) made under the ... [more ▼]

This study was conducted during three production cycles of the third year of vegetation. The main objective was to determine the production of dry matter (DM) and crude protein (CP) made under the influence of mixture and fertilization with nitrogen on P50 agrofond to alfalfa and orchard grass. To achieve these objectives, three variants of mixture were tested between alfalfa and cocksfoot that were applied to four rates of mineral fertilizers. The mixture 75% alfalfa (Medicago sativa L.) and 25% orchard grass (Dactylis glomerata L.) under the effect of dosing with N100P50achieved the highest production increase of DM on cycle I, 108% (5.24 Mg haDM) compared to the control, unfertilized alfalfa in pure culture (4.85 Mg ha DM). The highest increase forthe CP yield was obtained on cycle I from the 100% alfalfa fertilized with doses of N-1-1100P50, 122% (1230 kg haCP) from 100% alfalfa unfertilized (1009 kg ha CP). Alfalfa fertilized with N-1-1100P50 rate had the highest increases on total DM yield (106%, 10.64 Mg haDM) and on total quantity of CP(124%, 2304 kg ha CP). [less ▲]

Detailed reference viewed: 26 (1 ULg)
Full Text
Peer Reviewed
See detailInfluenza A strain-dependent pathogenesis in fatal H1N1 and H5N1 infections of mice
Garigliany, Mutien-Marie ULg; Habyarimana, Jean ULg; Lambrecht, Bénédicte et al

in Emerging Infectious Diseases (2010), 16(4), 595-603

Two different influenza A viruses showing no pathogenicity towards the laboratory mouse were forced to evolve by serial passaging. Although both adapted viruses evoked diffuse alveolar damage and showed a ... [more ▼]

Two different influenza A viruses showing no pathogenicity towards the laboratory mouse were forced to evolve by serial passaging. Although both adapted viruses evoked diffuse alveolar damage and showed a similar 50% mouse lethal dose and the same peak lung concentration, they elicited dramatically different pathological signatures and ARDS courses. In the absence of any virus labeling, a histologist unaware of which infection he was looking at could readily distinguish infections caused by these two viruses. This suggests that fatal infections caused by different highly virulent influenza A viruses do not necessarily share the same pathogenesis. The different histological pictures shown here refute the hypothesis of a single, universal “cytokine storm” underlying all fatal influenzal diseases. Research is thus crucially needed to identify underlying sets of virulence markers and to examine whether it might be advantageous to tailor treatment to the influenza virus pathotype. [less ▲]

Detailed reference viewed: 127 (58 ULg)
Full Text
See detailInfo Congrès: ALFEDIAM 2008 Bruxelles (Belgique): Insulinothérapie et monitoring continu du glucose.
RADERMECKER, Régis ULg

in Infusystèmes France (2008), 25(3), 23-24

Detailed reference viewed: 5 (0 ULg)
Full Text
See detailInfo Congres: nouveautés en matière de pancréas artificiel
RADERMECKER, Régis ULg

in Revue de l'Association Belge du Diabète (2008), 51(2),

Detailed reference viewed: 20 (4 ULg)
Full Text
Peer Reviewed
See detailInfo-congres. Effets d'une insulinotherapie intensive apres un infarctus du myocarde chez le patient diabetique de type 2 : resultats de l'etude DIGAMI-2.
Scheen, André ULg; Radermecker, Régis ULg; Philips, Jean-Christophe ULg

in Revue Médicale de Liège (2004), 59(9), 534-9

The results of DIGAMI-2 (<<Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction>>) trial were presented at the 40th scientific congress of the European Association for the Study of ... [more ▼]

The results of DIGAMI-2 (<<Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction>>) trial were presented at the 40th scientific congress of the European Association for the Study of Diabetes (EASD) in Munich on September 6, 2004. The main objective of this multicentre international trial was to confirm the positive results of the first DIGAMI trial published in 1995--1997. This pilot trial demonstrated that insulin-glucose infusion followed by a subcutaneous multidose insulin regimen reduces total mortality after 1 and 3 years in diabetic patients with acute myocardial infarction. DIGAMI-2, by comparing three groups of subjects receiving various interventions, aimed at determining the relative benefit resulting from the insulin-glucose infusion in the acute phase and that attributable to long-term intensive insulin therapy in a similar population of type 2 diabetic patients. No significant difference was observed between the three groups as far as total mortality and cardiovascular morbidity were concerned. These negative results may be explained by the absence of significant difference in blood glucose control between the three groups, by the fact that glycaemic targets were not reached in the intensive group and, last but not least, by a better management of other risk factors, allowing already markedly reduced cardiovascular morbidity and mortality in the reference group treated with conventional antidiabetic therapy. In conclusion, DIGAMI-2 argues for a multidisciplinary management of diabetic patients to reach strict glycaemic targets with an intensive insulin scheme and confirms the remarkable advances in cardiovascular protection thanks to an optimised global pharmacological approach combined with modern revascularisation procedures. [less ▲]

Detailed reference viewed: 53 (4 ULg)
Full Text
Peer Reviewed
See detailInfo-congres. Essai de prevention du diabete de type 1 par le nicotinamide: les lecons positives d'un essai clinique negatif (ENDIT).
Philips, Jean-Christophe ULg; Scheen, André ULg

in Revue Médicale de Liège (2002), 57(10), 672-5

ENDIT ("European Nicotinamide Diabetes Intervention Trial") is a large placebo-controlled randomised clinical trial that aimed at studying the efficacy of nicotinamide in the prevention of type 1 diabetes ... [more ▼]

ENDIT ("European Nicotinamide Diabetes Intervention Trial") is a large placebo-controlled randomised clinical trial that aimed at studying the efficacy of nicotinamide in the prevention of type 1 diabetes mellitus among first-degree relatives of type 1 diabetic patients with positive islet cell antibodies (ICA). The results presented at the last congress of the European Association for the Study of Diabetes (EASD) in Budapest do not evidence any significant difference in the risk of developing overt diabetes mellitus in the patients treated with nicotinamide (n = 274) as compared to those receiving placebo (n = 275) after 5 years of follow-up. Despite these negative results, positive lessons could be drawn from ENDIT: 1) the feasibility of a large long-standing multicentre European trial in a difficult research area; 2) the importance of large randomised controlled clinical trials to bring the evidence requested by "Evidence-Based Medicine"; 3) the predictive value of various risk markers to progress toward type 1 diabetes in first-degree relatives, especially the number of positive auto-antibodies; and 4) the urgent need to continue intensive research in this important field of preventive medicine. [less ▲]

Detailed reference viewed: 40 (0 ULg)
Peer Reviewed
See detailInfo-congres. Insulinotherapie pour prevenir le diabete de type 1 chez des sujets apparentes a haut risque: resultats negatifs du "Diabetes Prevention Trial-Type 1".
Scheen, André ULg; Philips, Jean-Christophe ULg

in Revue Médicale de Liège (2001), 56(7), 536-8

The results of the American multicentre "Diabetes Prevention Trial-Type 1" were presented by J. Skyler during the last congress of the American Diabetes Association in Philadelphia on June 23, 2001. The ... [more ▼]

The results of the American multicentre "Diabetes Prevention Trial-Type 1" were presented by J. Skyler during the last congress of the American Diabetes Association in Philadelphia on June 23, 2001. The prophylactic subcutaneous administration of low-dose insulin was not able to prevent the development of type 1 diabetes nor to preserve residual insulin secretion in young relatives at very high-risk of diabetes (> 50% in the next 5 years), selected upon genetic, immunological and metabolic criteria. [less ▲]

Detailed reference viewed: 33 (0 ULg)
Peer Reviewed
See detailInfo-congres. L'etude "MIRACL" ou "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering".
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(12), 1064-6

The results of the "MIRACL" trial ("Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering") were presented at the recent annual meeting of the American Heart Association in New Orleans last ... [more ▼]

The results of the "MIRACL" trial ("Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering") were presented at the recent annual meeting of the American Heart Association in New Orleans last November 2000. This study demonstrates that atorvastatin, at a daily dose of 80 mg starting within the first 24 to 96 hours after an acute coronary event (unstable angina or non-Q-wave acute myocardial infarction) and maintained for 4 months, improves the cardiovascular prognosis by decreasing the combined risk of death (any cause), nonfatal myocardial infarction, resuscitated cardiac arrest and worsening angina with new objective evidence of ischemia requiring urgent hospitalization (-16% versus placebo, p < 0.05). [less ▲]

Detailed reference viewed: 47 (2 ULg)
Peer Reviewed
See detailInfo-congres. L'etude HOPE: demonstration de la protection cardio-vasculaire du ramipril, un inhibiteur de l'enzyme de conversion de l'angiotensine.
Scheen, André ULg

in Revue Médicale de Liège (1999), 54(10), 835-6

The results of the HOPE ("Heart Outcomes Prevention Evaluation") study were presented at the XXIst Congress of the European Society of Cardiology in Barcelona (August 28-September 1, 1999). In addition ... [more ▼]

The results of the HOPE ("Heart Outcomes Prevention Evaluation") study were presented at the XXIst Congress of the European Society of Cardiology in Barcelona (August 28-September 1, 1999). In addition, results obtained in the large diabetic sub-population (38% of the 9541 patients included in the trial) were reported at the XXXVth Congress of the European Association for the Study of Diabetes in Brussels (September 28-October 2, 1999). The HOPE trial was terminated early because of a reduction of the relative risk (-22%, p < 0.000002) of major cardiovascular events in the group treated with ramipiril compared to the group receiving placebo. Such a favourable effect of ramipril was observed in non-diabetic subjects in secondary prevention and in diabetic patients in secondary or primary prevention. In the latter population, a significant reduction in the incidence of microangiopathic complications (nephropathy and retinopathy) was also demonstrated. [less ▲]

Detailed reference viewed: 51 (0 ULg)
Peer Reviewed
See detailInfo-congres. La cochrane collaboration, porte-parole de la medecine factuelle.
Scheen, André ULg

in Revue Médicale de Liège (2001), 56(11), 796-8

During the 9th International Cochrane Colloquium (Lyon October 9-13, 2001), around 700 participants discussed about how to make the evidence dissemination process more efficient in order to promote the ... [more ▼]

During the 9th International Cochrane Colloquium (Lyon October 9-13, 2001), around 700 participants discussed about how to make the evidence dissemination process more efficient in order to promote the Evidence-Based Medicine. The best evidence is summarized in systematic reviews of randomised and/or controlled clinical trials within the Cochrane Library which are prepared with a high methodological quality. However, these reviews should be completed to cover all medical domains, be actualized regularly, and, most importantly, be better known and more largely used by physicians in routine practice. All these objectives could not be attained without an official recognition and a financial support by the public health authorities. [less ▲]

Detailed reference viewed: 18 (2 ULg)
Peer Reviewed
See detailInfo-congrès. Le bisoprolol dans la décompensation cardiaque
Kulbertus, Henri ULg; Pierard, Luc ULg

in Revue Médicale de Liège (1998), 53(4), 223-4

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detailInfo-congres. Les lecons de la "United Kingdom Prospective Diabetes Study".
Scheen, André ULg; Lefebvre, Pierre ULg

in Revue Médicale de Liège (1998), 53(9), 576-8

The United Kingdom Prospective Diabetes Study (UKPDS) is the largest study ever performed in the field of diabetes. It has been carried on in more than 5000 patients with newly diagnosed type 2 diabetes ... [more ▼]

The United Kingdom Prospective Diabetes Study (UKPDS) is the largest study ever performed in the field of diabetes. It has been carried on in more than 5000 patients with newly diagnosed type 2 diabetes and followed during almost 15 years. The main goals of the study were to investigate the effects of improving blood glucose and/or blood pressure control on diabetic complications, and to compare the advantages and inconvenients of the most important pharmacological approaches. The results of the UKPDS have been presented at the last Congress of the European Association for the Study of Diabetes (EASD) in Barcelona, September 10-11, 1998. They essentially showed that improving blood glucose or arterial blood pressure control allows to significantly reduce the incidence of complications associated to diabetes. Best results were observed in individuals in whom treatments of both hyperglycemia and hypertension were intensified. For each risk factor, no threshold has been found so that every reduction in blood glucose or arterial pressure is accompanied by a nearly linear diminution in the incidence of diabetic complications. The type of pharmacological treatment appears to have a less prominent influence, even if metformin appears to exert the most favourable effects in the group of obese patients with type 2 diabetes. [less ▲]

Detailed reference viewed: 16 (0 ULg)
Full Text
Peer Reviewed
See detailInfo-congres. Optimalisation de la prise en charge du patient diabetique: une selection de quelques essais cliniques presentes au Congres 2004 de l'American Diabetes Association.
Scheen, André ULg; Radermecker, Régis ULg; Philips, Jean-Christophe ULg

in Revue Médicale de Liège (2004), 59(6), 407-12

The 64th scientific congress of the American Diabetes Association had a special session devoted to the presentation of the results from three clinical trials: 1) the first multicentre international trial ... [more ▼]

The 64th scientific congress of the American Diabetes Association had a special session devoted to the presentation of the results from three clinical trials: 1) the first multicentre international trial of pancreatic islet transplantation according to the so-called Edmonton protocol with the primary endpoint of restoring insulin independence in type 1 diabetic patients; 2) three pivotal studies of 30 weeks testing both the efficacy and safety of exenatide (exendin-4), a new insulin secretagogue that is a long-acting analogue of glucagon-like peptide-1, in patients with type 2 diabetes treated with either metformin, or a sulfonylurea, or a metformin-sulfonylurea combination; and 3) the "Collaborative AtoRvastatin Diabetes Study" (CARDS), a placebo-controlled primary prevention trial of cardiovascular complications using atorvastatin 10 mg in 2 838 at risk patients with type 2 diabetes. The main results and conclusions of these trials are briefly presented as they open new perspectives in the management of patients with type 1 or type 2 diabetes mellitus. [less ▲]

Detailed reference viewed: 22 (2 ULg)
Full Text
Peer Reviewed
See detailInfo-congres. Prevention du diabete de type 2 chez le sujet obese: premiers resultats avec l'orlistat dans l'etude XENDOS.
Scheen, André ULg

in Revue Médicale de Liège (2002), 57(9), 617-21

The results of the XENDOS study were presented by Professor Lars Sjostrom (Gothenburg, Sweden), on August 26, 2002, at the 9th International Congress on Obesity in Sao Paulo, Brazil. XENDOS (XENical in ... [more ▼]

The results of the XENDOS study were presented by Professor Lars Sjostrom (Gothenburg, Sweden), on August 26, 2002, at the 9th International Congress on Obesity in Sao Paulo, Brazil. XENDOS (XENical in the prevention of Diabetes in Obese Subjects) is a multicentre, randomised, double-blind, placebo-controlled, parallel-group prospective study performed in Sweden over a period of 4 years. The aim of XENDOS was to investigate the use of a weight loss agent (orlistat, Xenical) compared with lifestyle changes for the prevention of type 2 diabetes in obese patients (body mass index > or = 30 kg/m2). Weight loss was greater in the orlistat group (-6.9 kg; n = 1.640) than in the placebo group (-4.1 kg; n = 1.637; p < 0.001). Such a difference in weight reduction was sufficient to significantly reduce the cumulative incidence of type 2 diabetes (6.2% versus 9.0%; p = 0.0032; relative risk reduction of 37.3%). The difference was especially remarkable in obese patients with impaired glucose tolerance (21% of the cohort), with a reduction of conversion to diabetes from 28.8% in the placebo group to 18.8% in the orlistat group (p < 0.005) and a number needed to treat to avoid one event of 11 only. Significant and sustained reductions in cardiovascular risk factors such as arterial blood pressure and lipid levels were also observed in the orlistat group as compared to the placebo group. XENDOS is the first study demonstrating that an antiobesity agent, like orlistat, is able to reduce the progression to diabetes in obese subjects as compared with lifestyle changes alone. [less ▲]

Detailed reference viewed: 114 (0 ULg)
Peer Reviewed
See detailInfo-congres. Prevention pharmacologique de la progression de la diminution de la tolerance au glucose vers le diabete de type 2: effets favorables de la metformine et de l'acarbose.
Scheen, André ULg

in Revue Médicale de Liège (2001), 56(10), 727-30

We report the positive results of two large prospective studies of pharmacological prevention of type 2 diabetes presented at the EASD Congress in Glasgow, September 12, 2001. In the "Diabetes Prevention ... [more ▼]

We report the positive results of two large prospective studies of pharmacological prevention of type 2 diabetes presented at the EASD Congress in Glasgow, September 12, 2001. In the "Diabetes Prevention Program", metformin (2 x 850 mg/day), a biguanide compound, reduces the progression from impaired glucose tolerance towards type 2 diabetes by 31% (p < 0.001) while in the "STOP-NIDDM trial", acarbose (3 x 100 mg/day), an alpha-glucosidase inhibitor, diminished it by 24% (p < 0.002). These results are, however, less marked than those obtained with lifestyle modifications including better dietary habits and increased physical exercise (-58% versus control group, p < 0.001). [less ▲]

Detailed reference viewed: 11 (0 ULg)
Peer Reviewed
See detailInfo-congres. Recherche en diabetologie: rayonnement europeen de l'Ecole de Liege.
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(10), 960-7

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailInformal caregiver involvement in innovative home care projects in Belgium
Lopez Hartmann; Van Durme, Thérèse; Maggi, Patrick ULg et al

Poster (2013, April)

Detailed reference viewed: 3 (1 ULg)
See detailInformation - orientation : articulation
Wouters, Chantal; Broonen, Jean-Paul ULg

in Conseil de l'Education et de la Formation. Rapport 1995-1996 (Ed.) De l'enseignement secondaire à l'enseignement supérieur : Orientation - Information (1996)

Detailed reference viewed: 9 (2 ULg)